Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Pharmacol Rep ; 70(6): 1079-1088, 2018 Dec.
Article in English | MEDLINE | ID: mdl-30308458

ABSTRACT

BACKGROUND: Gemcitabine is a standard chemotherapeutic agent for patients suffering from pancreatic cancer. However, the applied therapy is not effective due to the resistance of tumor cells to cytostatics, caused by inefficiency of the apoptotic mechanisms. Herein, we present the hypothesis that melatonin and its metabolite N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK) modify the effect of gemcitabine on PANC-1 cells and that this phenomenon is dependent on the modulation of apoptosis. METHODS: PANC-1 cells have been incubated with melatonin, AFMK or gemcitabine alone or in combination to determine the cytotoxity and proliferative effects. In subsequent part of the study, cells were harvested, the proteins were isolated and analyzed employing immunoprecipitation/immunoblotting. RESULTS: Incubation of PANC-1 cells with gemcitabine resulted in upregulation of pro-apoptotic bax and caspases proteins expression, downregulation of anti-apoptotic Bcl-2, heat shock proteins (HSPs) and modulation of cellular inhibitors of apoptosis (IAPs). Both melatonin and AFMK administered to PANC-1 in combination with gemcitabine inhibited the production of HSP70 and cIAP-2 as compared to the results obtained with gemcitabine alone. These changes were accompanied by upregulation of Bax/Bcl-2 ratio and reduction of procaspases-9 and -3 abundance, followed by an increase in the formation of active caspase of PANC-1 cells with combination of gemcitabine plus low doses of melatonin or AFMK led to enhanced cytotoxicity and resulted in the inhibition of PANC-1 cells growth as compared to effects of gemcitabine alone. CONCLUSION: Melatonin and AFMK could improve the anti-tumor effect of gemcitabine in PANC-1 cells presumably through the modulation of apoptotic pathway.


Subject(s)
Antimetabolites, Antineoplastic/metabolism , Apoptosis/drug effects , Deoxycytidine/analogs & derivatives , Kynuramine/analogs & derivatives , Melatonin/metabolism , Pancreatic Neoplasms/metabolism , Antimetabolites, Antineoplastic/administration & dosage , Apoptosis/physiology , Cell Line, Tumor , Cell Survival/drug effects , Cell Survival/physiology , Deoxycytidine/administration & dosage , Deoxycytidine/metabolism , Dose-Response Relationship, Drug , Drug Synergism , Humans , Kynuramine/administration & dosage , Kynuramine/metabolism , Melatonin/administration & dosage , Gemcitabine
2.
J Neurochem ; 98(6): 2023-33, 2006 Sep.
Article in English | MEDLINE | ID: mdl-16945113

ABSTRACT

We assessed the effects of melatonin, N(1)-acetyl-N (2)-formyl-5-methoxykynuramine (AFMK) and N(1)-acetyl-5-methoxykynuramine (AMK) on neuronal nitric oxide synthase (nNOS) activity in vitro and in rat striatum in vivo. Melatonin and AMK (10(-11)-10(-3) m), but not AFMK, inhibited nNOS activity in vitro in a dose-response manner. The IC(50) value for AMK (70 microm) was significantly lower than for melatonin (>1 mm). A 20% nNOS inhibition was reached with either 10(-9) m melatonin or 10(-11) m AMK. AMK inhibits nNOS by a non-competitive mechanism through its binding to Ca(2+)-calmodulin (CaCaM). The inhibition of nNOS elicited by melatonin, but not by AMK, was blocked with 0.05 mm norharmane, an indoleamine-2,3-dioxygenase inhibitor. In vivo, the potency of AMK to inhibit nNOS activity was higher than that of melatonin, as a 25% reduction in rat striatal nNOS activity was found after the administration of either 10 mg/kg of AMK or 20 mg/kg of melatonin. Also, in vivo, the administration of norharmane blocked the inhibition of nNOS produced by melatonin administration, but not the inhibition produced by AMK. These data reveal that AMK rather than melatonin is the active metabolite against nNOS, which may be inhibited by physiological levels of AMK in the rat striatum.


Subject(s)
Corpus Striatum/enzymology , Enzyme Inhibitors/pharmacology , Kynuramine/analogs & derivatives , Nitric Oxide Synthase Type I/antagonists & inhibitors , Animals , Brain/metabolism , Carbolines , Dose-Response Relationship, Drug , Harmine/analogs & derivatives , Harmine/pharmacology , In Vitro Techniques , Kinetics , Kynuramine/administration & dosage , Kynuramine/metabolism , Kynuramine/pharmacology , Male , Melatonin/administration & dosage , Melatonin/metabolism , Melatonin/pharmacology , Rats , Rats, Wistar
3.
Eur J Pharmacol ; 142(3): 447-51, 1987 Oct 27.
Article in English | MEDLINE | ID: mdl-3428356

ABSTRACT

Intraventricular administration of the tryptophan metabolites l-kynurenine (2-32 micrograms) and kynuramine (0.064-8 micrograms) facilitated lordosis behavior in estrogen-primed ovariectomized rats. The facilitatory effects of these drugs were not attenuated by pretreatment with the progesterone antagonist RU 38486, indicating that the effects were not mediated by release of adrenal progesterone. It is suggested that l-kynurenine and kynuramine may serve a physiological role in the modulation of female sexual behavior.


Subject(s)
Kynuramine/pharmacology , Kynurenine/pharmacology , Propiophenones/pharmacology , Sexual Behavior, Animal/drug effects , Animals , Estradiol/pharmacology , Estrenes/pharmacology , Female , Glucocorticoids/antagonists & inhibitors , Injections, Intraventricular , Kynuramine/administration & dosage , Kynurenine/administration & dosage , Mifepristone , Rats
SELECTION OF CITATIONS
SEARCH DETAIL
...